[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kiminori Kimura, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645405","phase-2-a-phase-2-study-of-foscenvivint-in-liver-cirrhosis-patients-caused-by-hivhcv-co-infection-with-hemophilia-100645405",false,"NCT07681089","A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV\u002FHCV Co-infection With Hemophilia.","A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV\u002FHCV Co-infection in the Setting of Hemophilia.","OP-724-H202","Inclusion Criteria:\n\n* Patients with hemophilia and liver cirrhosis caused by HIV\u002FHCV co-infection who meet both of the following criteria:\n\n  1. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \\\u003C200 copies\u002FmL and a CD4-positive T lymphocyte count of ≥200 cells\u002FµL at screening.\n  2. Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.\n\n     * Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9).\n     * Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:\n\n  \u003C!-- -->\n\n  1. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.\n  2. Abdominal CT showing changes in liver morphology and\u002For findings suggestive of portal hypertension.\n\n     * Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology.\n* Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.\n* Patients with current malignancy or a history of malignancy within 3 years before registration.\n* Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation.\n* Patients with active AIDS-defining disease requiring treatment. -","MALE","18 Years","79 Years",{"count":21,"type":22},4,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a phase 2 study designed to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV\u002FHCV co-infection in the setting of hemophilia.",[28],"Liver Cirrhosis",[28,30,31],"Hemophilia","HIV\u002FHCV co-infection","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":22},"2026-09-01",{"date":40,"type":22},"2028-03-31",{"name":42,"class":43},"Kiminori Kimura, MD","OTHER",3,""]